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NATURE OF INHIBITION OF ULTRAVIOLET ERYTHEMA
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Prevention of ultraviolet erythema of the skin by iontophoretically introducing
Pyribenzamine solution prior to exposure to the ultraviolet lamp, was reported by
Kurtin, Bierman and Yontef (1). The capacity of the "antihistaminic" drug
Pyribenzamine to exert this effect indicated to these authors "that erythema
solare is dependent upon the action of released histaminic substance into the
tissues". The present study was undertaken to ascertain whether the ultra-
violet erythema-inhibiting effect is indeed due to "antihistaminic" action or
whether it is merely due to absorption by Pyribenzamine of those wavelengths
which produce ultraviolet erythema. For this purpose we tested the effects of
Pyribenzamine hydrochloride, and Benadryl hydrochloride, substances which
both have a high "antihistaminic" activity but which have entirely different
absorption curves in the ultraviolet part of the spectrum: Pyribenzamine has a
high extinction peak in the zones producing ultraviolet erythema (Fig. 1). Bena-
dryl shows no extinction at 2900 to 3100 A units but a moderately high extinction
in the region of 2537 A units (Fig. 2).
EXPERIMENTAL
A. Tests with iontophoresis of "antihistaminic" drugs preceding
ultraviolet irradiation
In these tests Pyribenzamine 5% or 10% aqueous solution, Benadryl 5% or
10% aqueous solution and distilled water alone were introduced for from 90
seconds to 5 minutes by iontophoresis into the skin of the forearms, back or ab-
domen from the positive pole. In some experiments a zinc electrode and in
others a lead electrode was used. The current density varied from 0.11 MA
to 0.8 MA per square centimeter. In every test 5% or 10% solutions of both
Pyribenzamine and Benadryl were compared. From 10 minutes to 4- hours after
iontophoresis the treated sites and in many tests also a blank control site were
exposed to 3 to 6 erythema doses of ultraviolet radiation from a Hanovia Super S
hot quartz ultraviolet lamp at a distance of 30 inches or at a distance of 3 to 6
inches with a Rose "type 4005" cold quartz ultraviolet lamp. In all instances
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FIG. 1. Absorption curve of Pyribenzamine hydrochloride.
the irradiated sites were observed after 18 to 24 hours and often additional ob-
servations were made at 3 to 96 hours.
The results of these tests are shown in Tables 1 and 2.
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B. Tests with ultraviolet irradiation through qwirtz cups containing
"antihistaminic" drugs
In these tests Pyribenzamine 5% or 10% aqueous solution, Benadryl 5%
or 10% aqueous solution and distilled water alone were filled into cups made of
3BO
fused quartz which permit the passage of ultraviolet radiation (Mayer (2)).
These cups were 3.0 cm wide, 1.9 cm high and their walls were 0.1 cm thick. In
every test 5% or 10% solutions of both Pyribenzamine and Benadryl were com-
pared. The amount of solution in the cups varied from quantities barely enough
to cover their bottoms to quantities forming layers about 1 cm high. In each
series of tests equal quantities of solutions were filled into all cups. A card-
board stencil was used to hold in place the 3 or 4 cups used in each test and at
Lo4.
Fio. 2. Absorption curve of Benadryl hydrochloride.
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the same time to protect the skin surrounding the quartz cups from exposure to
radiation. Care was taken to have the bottoms of all cups in contact with the
underlying skin without their pressing so hard that relative blanching of the skin
occurred. The sites covered by the quartz cups were then exposed to 3 to 6
TABLE 1
Multiple erythema doses of Hot Quartz ultraviolet irradiation after preceding Ionlophoresis
of solutions of "Antihistaminic" drugs*
SUBJECT PBZ 5%oRlO% AQ. BEN. 5% On 10% AQ. WATER ALONE ENTREATED SKIN SITE
Ba. + ++
K. 0 ++ ++
W. ? +± ++
Be. (+) +-++ ++ +—++
J. + +-++ ++ ++
M. + ++ ++ ++
0. +-++ ++ ++ +-++
z. + +-++ +-++ +—++
Kie. + ++ ++
a. + ++ ++
Ku. (+) +-++ ++
Ba. (+) ++ ++
* ? Questionable reaction.(+) = Very slight erythema.
+ = Definite erythema.
++ = Very intense erythema.
TABLE 2
Multiple erythema doses of Cold Quartz ultraviolet irradiation after preceding lontophoresis of
solutions of "Arttihistaminic" drugs
SUBJECT pBz. 5% oi 10% AQ.SQL. BEN. 5% OR 10% AQ.SOL. WATER ALONE ENTREATED SKIN SITE
Be. 0 (+) (+) (+)
J. (+) +-++ ++ ++
M. (+) ++ ++ ++
0. + ++ ++ ++
z. 0 + + +
Kie. (+) + +
R. (+) + +
Ku. (+) +-++ ++
Ba. + ++ ++
Ru. + +-++ ++
erythema doses of ultraviolet radiation from a Hanovia Super S hot quartz
ultraviolet lamp at 30 inches distance or from a Rose "type 4005" cold quartz
ultraviolet lamp at 3 to 6 inches distance. In all instances the irradiated sites
were observed after 18 to 24 hours and often additional observations were made
at 3 to 96 hours.
The results of these tests are shown in Tables 3 and 4.
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COMMENT
The experiments reported here were designed to ascertain whether the sun-
burn-preventing effects of Pyribenzamine solution reported by Kurtin et al (1)
are indeed due to "antihistaminic" action of Pyribenzamine in the skin or are
merely due to a filtering action i.e. to absorption of the erythema-producing
wavelengths. The absorption curve of Pyribenzamine solution (Fig. 1) strongly
suggested such a filtration effect rather than "antihistaminic" action. We be-
lieve that our experimental results speak against the "antihistaminic" nature of
the ultraviolet erythema-inhibiting effect and strongly support the assumption
that we are dealing with a filtration effect similar to that of para-aminobenzoic
Fm. 3. I-lot quartz ultraviolet radiation after preceding iontophoresis of Pvribenzaminc
5% solution (Site I), distilled water (Site II) and Benadryl 5% solution (Site III).
acid, tannic acid, menthyl salicylate and a legion of other substances. In favor
of this explanation are the following findings:
1. Pyribenzamine solution when introduced by iontophoresis significantly
lessens ultraviolet erythema as compared with normal control sites. However,
it does so to a much greater degree and with greater regularity when "anti-
histaminic" action can be ruled out i.e. when the Pyribenzamine solution in a
quartz cup is interposed between the source of the radiation and the skin.
2. Benadryl solution, which also has a high "antihistaminic" activity, when
introduced by iontophoresis lessens ultraviolet erythema only in a minority of
subjects and then only to a slight degree. However, it does so also and, as a
matter of fact, more distinctly when "antihistaminic" action can be ruled out
i.e. when the solution in a quartz cup is interposed between the source of the
radiation and the skin. The slight effect produced by Benadryl appears to be
due to it's capacity to absorb the wavelength in the region of 2537 A, i.e. in-
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hibition of the "cold quartz" part of the ultraviolet erythema (see Fig. 2 and
Table 4).
Fin. 4. Irradiation of skin through quartz cups.
Left side Right side(i-tot quarts Lamp) (coil kuarts Lamp)
water 2 plus water 1 to 2 plus
Pbz 0 Pbz 0
Ben 1 to 2 plus Beu 0
blank cup 2 plus blank cup 1 plus
Note fine ring of erythema at sites 2 and 3 on the right side; this is due to passage of
ultraviolet radiation between cup and stencil.
Of how much practical, i.e. preventive and therapeutic, importance is this
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violet spectrum? Should Pyribenzamine be employed as one of the standard
filters in sunburn preventives? It seems to us that such use is oniy indicated in
selected cases in which the combined antipruritic (Feinberg and Bernstein (3),
Sulzberger, Baer and Levin (4)) and light-filtering action of Pyribenzamine is
especially necessary. Cases of eczema solare, allergic eczematous contact-
type dermatitis associated with features of light-sensitization, some cases of
TABLE 3
Multiple erythema doses of Hot Quartz ultraviolet irradiation through Quartz Cups containing
solutions of "Antihistaminic" drugs
SUBJECT WATER ALONE IN CUP CUP ALONE
Bo. 0 + +
Ba. 0 +
Ba. 0 0 +
Ba. 0 + ++
KI. 0 0 +
Ki. 0 0 +
Ki. 0 + ++
IL 0 + ++
Kr. 0 ++ ++
Ka. 0 +-++ ++ ++
w. 0 +—++ ++ ++
S. 0 +-++ ++ ++
Br. 0 +-++ ++ ++
TABLE 4
Multiple erythema doses of Cold Quartz ultraviolet irradiation through Quartz Cups containing
solutions of "Antihistaminic" drugs
SUBJECT pnz. 5%o, 10 % AQ.SOL. IN CUP
BEN. 5% OR 10% AQ.
SOL. IN CUP WATER ALONE IN CUP CUP ALONE
Bo. 0 + +
K!. 0 + 0
Ka. 0 0 + +
W. 0 0 +-++ +
8. 0 0 + +
Br. 0 0 + +
herpes simplex elicited by sunlight etc. may belong to this category. However,
routine use of Pyribenzamine as a sunfilter appears contraindicated because re-
peated application over large areas could, by absorption through the skin,
theoretically lead to systemic side-effects and because of the possibility of allergic
eczematous contact-type sensitization (4) which appears to be greater from topi-
cal use of Pyribenzamine than from some of the other topically employed sun-
filters (salicylic acid derivatives, tannic acid etc.).
Should large doses of Pysibenzamine routinely be administered by mouth as a
"systemic" sunburn preventive? In our opinion this also appears contraindicated
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because there is no evidence at hand that such use in the doses generally used at
present would be effective in preventing sunburn; and because under usual condi-
tions it is not reasonable to take a chance on possible side effects from systemic
administration when adequately protective, topically applied "sunburn pre-
ventives" are available. However, here too there may be exceptional cases which
warrant the oral administration of Pyribenzamine. Such a possibility must be
thought of in view of the cases of urticaria solare (<3703 A) reported by Rubin,
Beal and Rothman (5) in whom administration of Pyribenzamine by mouth per-
mitted "non-specific" desensitization to light. In their cases, in addition to the
reasons for the occurrence of desensitization given by Rubin et al, a possible
"sunfilter" effect of orally administered Pyribenzamine present in the skin should
be considered.
CONCLUSIONS
Experiments are reported in which Pyribenzamine and Benadryl solutions were
introduced into the skin by iontophoresis prior to ultraviolet irradiation and other
experiments in which these solutions in quartz cups were interposed between the
source of radiation and the skin.
Pyribenzamine solution is a good filter for protecting the skin against cry-
thema due to the ultraviolet part of the light spectrum. The results of the
present experiments indicate that this effect is due principally to the property of
Pyribenzamine to filter out the wavelengths producing ultraviolet erythema
rather than being due to an "antihistaminic" action. Benadryl solution, though
possessing "antihistaminic" action, has only a very minor action of interfering
with ultraviolet erythema; this effect can be explained by its absorption of wave-
lengths in the region of 2537 A units.
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DISCUSSION
DR. STEPHEN ROTHMAN: Originally, the observation that Pyribenzamine,
when injected locally, inhibits the development of ultraviolet erythema led to
the erroneous conclusion that sunburn has a histaminic mechanism. This error
is quite analogous to that one which I committed 22 years ago when I first ob-
served that the injection of procaine, preceding irradiation, inhibits the develop-
ment of ultraviolet erythema. I thought that this was due to the anesthetic
effect of procaine and, therefore, sunburn must depend on intact sensory nerve
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endings. However, as cocaine did not have a similar effect, another explanation
had to be sought for. It was found that the inhibition is due to the screening
effect of the p-aminobenzoic radical in procaine.
Little known is the fact that the 2536 Angstrom line of the mercury arc causes a
short lasting erythema without any edema and with no subsequent pigmentation
on human skin. This was first demonstrated by Hausser and Vahie in 1921.
I believe that the results of Drs. Baer and Kline with the cold quartz lamp which
emits a strong 2536 A line can be explained as being due to the remarkable short
lasting effect of this line which is absorbed also by Benadryl.
The "desensitization" of solar urticaria by Pyribenzamine to which Dr. Baer
referred is quite obviously an antihistaminic action. In the cases published from
the University of Chicago a decrease of sensitivity 6 to 8 times could be achieved
with both Benadryl and Pyribenzamine. Thus, this effect has absolutely no-
thing to do with the absorption spectrum of Pyribenzamine.
Dn. THEODORE B. BERNSTEIN: It was very interesting to hear this paper con-
cerning the nature of the inhibiting effect of Pyribenzamine upon erythema pro-
duced by ultraviolet irradiation. We have been investigating this problem, using
a slightly different method. Feinberg, Lovejoy and I prepared 2% concentra-
tions of Pyribenzamine and several other antihistaminics in an ointment base.
Equal amounts of each of these preparations were applied to areas on the backs
of several subjects, and left on for varying periods of time, after which the cream
was carefully removed. These sites were then irradiated. Different erythema
doses were used and the interval of time between the removal of the ointment and
the beginning of irradiation also varied. Our results were very similar to those of
Doctors Baer and Kline, inasmuch as we found Pyribenzamine to be the most
effective of our materials in inhibiting ultraviolet erythema. Benadryl was not
as effective as Pyribenzamine. A placebo ointment consisting of the same oint-
ment base but with no added antihistaminic agent did not prevent irradiation
erythema. We also found that irradiation had to be done within 30 minutes of
the application of the antihistaminic to the skin. If we waited longer than 30
minutes the inhibition produced by Pyribenzamine was almost nil. The cry-
thema ordinarily produced by up to 5 erythema doses at untreated skin sites was
prevented by prior application of the Pyribenzamine ointment.
DR. R. L. MAYER: The explanation Dr. Baer and Dr. Kline have given for
the protection against ultra-violet light by antihistaminics seems correct to me.
I also believe that most of this action can be explained on the basis of physical
absorption and not due to a specific antihistaminic. On the other hand, there are
observations by Poupa (Nature, 161, 235, 1948) on the influence of antihis-
taminics on Daphnia which suggest that under certain circumstances anti-
histaminics may also confer a degree of biological protection to ultra-violet light.
Whether this also applies to the protection of human skin remains to be shown.
DR. SAMUEL M. PECK: I wish to congratulate Dr. Baer and Dr. Kline on a
very fine piece of work. I have always felt that Kurtin did not realize that he
was demonstrating in this work a purely physical phenomenon rather than one
that has to do with anti-histaminic reactions. This holds true as far as light
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filtration is concerned. However, we must bear in mind that iontophoresis with
Pyribenzamine has demonstrated that, not only has it an antihistaminic effect,
but a much more nonspecific effect in that it tends to reduce even the action of
primary irritants on the skin. When that is accomplished, there is less tendency
to pigmentation. I say this because it has been demonstrated by myself as well
as by other observers, that when a cell is injured by an inflammatory reaction,
pigment formation can occur even in the absence of light as part of the regenera-
tive process.
Dn. BAER: I wish to thank the discussors for their very pertinent remarks.
I can add only that when you introduce Pyribenzamine solution by iontophoresis
the protective effect against ultraviolet erythema lasts longer than one-half hour.
Dr. Rubin is at present studying this particular phase and although I cannot
make any definite statements, I can say that this effect lasts for many hours.
